Jeffrey Cooper, OD
Corneal and Contact Management · Brooklyn, NYNPI 1295800050
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,660 of the $52,327 with a category attached, or 89.2%. Visioneering Technologies, Inc. accounts for 91.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $25,063 and has fallen 95.7% since, to $1,069 in 2025. Among corneal and contact management clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $299.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Visioneering Technologies, Inc.$48K
- Alcon$752
- Coopervision Inc.$653
- Bausch & Lomb Americas Inc.$362
- Oyster Point Pharma, Inc.$350
- Sun Pharmaceutical Industries Inc.$292
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$46,66089%
- Food & beverage$5,61311%
- Education$180%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Visioneering Technologies, Inc. | 12 | $47,747 |
| Alcon | 21 | $752 |
| Coopervision Inc. | 17 | $653 |
| Bausch & Lomb Americas Inc. | 17 | $362 |
| Oyster Point Pharma, Inc. | 19 | $350 |
| Sun Pharmaceutical Industries Inc. | 8 | $292 |
| AbbVie(2 entities) | 14 | $243 |
| Novartis | 11 | $221 |
| Sight Sciences, Inc. | 4 | $204 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $184 |
| Shire North American Group Inc | 5 | $174 |
| Lombart Brothers, Inc. | 2 | $150 |
| Dompe US, Inc. | 5 | $142 |
| Kala Pharmaceuticals, Inc. | 7 | $141 |
| Tarsus Pharmaceuticals, Inc. | 5 | $135 |
| Eyevance Pharmaceuticals LLC | 6 | $130 |
| Harrow Eye, LLC | 3 | $80 |
| Johnson & Johnson Vision Care, Inc. | 3 | $77 |
| Amgen(2 entities) | 4 | $74 |
| Aerie Pharmaceuticals, Inc. | 3 | $67 |
| Rxsight Inc | 1 | $48 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $37 |
| ABB Con-cise Optical Group LLC | 1 | $27 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,327 in reported general payments places this provider in the 95th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 50 | $30,427 |
| XiidraLifitegrast | 23 | $19,889 |
| RestasisCyclosporine | 18 | $18,055 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $10,330 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $2,928 |
| Travoprost | 15 | $2,398 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $1,639 |
| Latanoprost | 199 | $1,364 |
| Prednisolone Acetate | 32 | $1,118 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $738 |
| Timolol Maleate | 40 | $515 |
| Dorzolamide Hcl | 20 | $255 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $362 | $50,31673 claims |
| AbbVieRestasis | $243 | $18,05518 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $67 | $10,33014 claims |
| AlconSimbrinza | $752 | $2,92815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 corneal and contact management providers in New York.
Other corneal and contact management in Brooklyn
- Stanislav IlyushaBrooklyn$3K
- Michael KiselowBrooklyn$3K
- Jacqueline ChangBrooklyn$388
- Lindsey ChanBrooklyn$152
- Michele LaganaHoneoye Falls$248K
- Avani DaveBuffalo$122K
- Kevin RosinNew York$59K
- Kevork NiksarliNew York$27K
- Richard MalaraBaldwinsville$8K
- David BraunSyracuse$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.